Loading...
XSHG
688068
Market cap1.18bUSD
Oct 09, Last price  
84.54CNY
1D
-1.10%
1Q
-31.99%
IPO
83.86%
Name

Beijing Hotgen Biotech Co Ltd

Chart & performance

D1W1MN
XSHG:688068 chart
P/E
—
P/S
19.43
EPS
—
Div yield, %
0.23%
Shrs. gr., 5y
0.40%
Rev. gr., 5y
-4.70%
Revenues
404m
-20.99%
122,195,767142,088,955187,123,050210,412,322513,533,6295,369,203,7603,556,551,568547,836,199510,900,037403,655,200
Net income
-216m
L+13.11%
28,799,46530,072,30548,140,84033,877,759112,066,6372,185,763,396944,736,63428,922,438-191,004,561-216,045,116
CFO
-83m
L+124.30%
45,540,32322,950,09255,036,63919,372,378164,624,0802,644,481,598978,753,167-25,386,208-37,162,581-83,356,823
Dividend
Jul 03, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Hotgen Biotech Co., Ltd. specializes in the complete process, from research and development to manufacturing and sales, of in-vitro diagnostic (IVD) solutions for medical and public safety purposes within the biomedical field. Their comprehensive range of products incorporates cutting-edge technologies like drug detection, CDC-compliant methods, up-conversion luminescence, colloidal gold, CLIA, sugar capture, microfluidics, and gene detection. These advanced diagnostic tools are designed to identify a broad spectrum of targets, including intestinal microorganisms, pathogens causing gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, various infectious diseases, Ebola virus antigens, biological warfare agents, other microorganisms, and mycotoxins. The company, founded in 2005, is headquartered in Beijing, China.

Key people

Zhongchao Xie
Chief Financial Officer · since 2023
Changqing Lin
Chairman of the Board, General Manager · since 2019
Jianguo Chen
Deputy General Manager · since 2022
Xiaochi Jie
Deputy General Manager · since 2024
Yanzhao Li
Deputy General Manager · since 2025
Jia Liu
Deputy General Manager · since 2025
Haifeng Sun
Deputy General Manager · since 2018
Shaohua Yu
Deputy General Manager, Director · since 2019
Wei Min
Director of Biochemiluminescent Reagent R&D Transformation Department, Director of Reagent Quality Assurance Department · since 2019
Director · since 2025
Xiaoli Liu
Director · since 2024
Shen Qi
Director · since 2019
Yongzhan Shi
Deputy General Manager, Secretary of the Board, Director · since 2023
Lida Xu
Staff Elected Director · since 2025
Xin Zhou
Director · since 2019
Shukui Dong
Independent Director · since 2019
Independent Director · since 2019
Mengjuan Ii
Independent Director · since 2025
Xiaoge Xu
Independent Director · since 2024
IPO date
Sep 30, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT